fda compounding semaglutide warning september 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Warns 30 Telehealth Companies

Common ones include nausea, digestive changes, fatigue, or headaches especially during the initial titration phase

Frequently Asked Questions References [1] [2] National Library of Medicine, Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing, Gwyer, D., Wragg, N., Wilson, S., 2017 [3] [5] National Library of Medicine, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi, N., Hahamyan, H., Salata, M., Karns, M., Calcei, J., Voos, J., Apostolakos, J., July 2025 [4] National Library of Medicine, Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway, Hsieh, M., Lee, C., Cheh, H., Chang, G, Huang, H., Lin, Y., Pang, J., October, 2020

Rigorous in-house and third-party testing No matter what we develop, all batches produced undergo rigorous in-house and third-party testing to ensure that the safety, quality, and potency of our products uphold our company standards

A: Allergy injections are covered once the deductible is met, $10 copay at the PCP office, $20 copay at the specialist office

The full study runs 12 weeks, which will provide statistical power, clear comparison and an understanding of trajectory over time